The reorganization plan of Fujian Aonong Biological Technology Group Incorporation (603363.SH) has been completed.

Fujian Aonong Biological Technology Group Incorporation (603363.SH) announced that on December 26, 2024, the company received the Civil Ruling No. (2024) Min 06 Pao 107-II issued by the Intermediate People's Court of Zhangzhou City, Fujian Province, confirming the completion of the implementation of the "Fujian Aonong Biological Technology Group Co., Ltd. Restructuring Plan" and terminating the restructuring process of Aonong Biological. Through the restructuring process, the company introduced restructuring investors and secured support from creditors, effectively resolving the debt crisis, improving the company's asset-liability structure and financial condition, and safeguarding the legitimate rights and interests of all creditors and small and medium-sized investors to the maximum extent. After the completion of the restructuring, the company will seize the opportunity to form an industrial layout with feed processing as the foundation, supplemented by breeding and food, adhere to prudent management, steadily promote vertical integration of the industry, optimize and upgrade Aonong Biological's operations with the support and empowerment of restructuring investors, further enhance the comprehensive competitiveness and sustainable operation capability of Aonong Biological. At the same time, in accordance with the relevant provisions of the "Shanghai Stock Exchange Listing Rules" and the "Shanghai Stock Exchange List Company Self-discipline Supervision Guidelines No. 13 - Bankruptcy and Restructuring Matters," the company has eliminated the risks of delisting warning due to the acceptance of restructuring by the court. On December 27, 2024, the company applied to the Shanghai Stock Exchange for the removal of the delisting warning due to the acceptance of restructuring by the court.